Development of Eganelisib, a First-in-Class PI3Kgamma Inhibitor for Next Generation Macrophage Reprogramming Cancer Immunotherapy
Time: 12:30 pm
day: Day Two Track B AM
Details:
• Discovery of Eganelisib and characterization of MOA
• Summary of Eganelisib clinical development program with a focus on translational data
